Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Current Deferred Revenue (2016 - 2021)

Abeona Therapeutics (ABEO) has 11 years of Current Deferred Revenue data on record, last reported at $296000.0 in Q4 2021.

  • For Q4 2021, Current Deferred Revenue changed 0.0% year-over-year to $296000.0; the TTM value through Dec 2021 reached $296000.0, changed 0.0%, while the annual FY2021 figure was $296000.0, 0.0% changed from the prior year.
  • Current Deferred Revenue reached $296000.0 in Q4 2021 per ABEO's latest filing, roughly flat from $296000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $2.6 million in Q4 2017 and bottomed at $296000.0 in Q4 2018.
  • Average Current Deferred Revenue over 5 years is $575444.4, with a median of $296000.0 recorded in 2018.
  • Peak YoY movement for Current Deferred Revenue: surged 331.89% in 2017, then crashed 88.62% in 2018.
  • A 5-year view of Current Deferred Revenue shows it stood at $2.6 million in 2017, then plummeted by 88.62% to $296000.0 in 2018, then changed by 0.0% to $296000.0 in 2019, then changed by 0.0% to $296000.0 in 2020, then changed by 0.0% to $296000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $296000.0 in Q4 2021, $296000.0 in Q3 2021, and $296000.0 in Q2 2021.